[
    [
        {
            "time": "",
            "original_text": "全球新冠疫苗若研发成功对药用玻璃需求测算【太平洋医药】",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "研发成功",
                    "药用玻璃",
                    "需求测算",
                    "太平洋医药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "全球新冠疫苗若研发成功对药用玻璃需求测算【太平洋医药】",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "复星集团总裁助理陈波：优秀品牌是企业的牵引机和助推器",
            "features": {
                "keywords": [
                    "复星集团",
                    "总裁助理",
                    "陈波",
                    "优秀品牌",
                    "企业",
                    "牵引机",
                    "助推器"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "企业品牌"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星集团总裁助理陈波：优秀品牌是企业的牵引机和助推器",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "复星医药(02196-HK)子公司新药临床试验注册审评获药监局受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "新药",
                    "临床试验",
                    "药监局",
                    "受理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196-HK)子公司新药临床试验注册审评获药监局受理",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药(02196-HK)子公司新药获台卫生福利部同意用于晚期实体瘤治疗临床试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "新药",
                    "台湾",
                    "卫生福利部",
                    "晚期实体瘤",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196-HK)子公司新药获台卫生福利部同意用于晚期实体瘤治疗临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]